EUCTR2008-001090-15-DE进行中（未招募）1 期
Randomized, double-blind Phase II study of Docetaxel + Sorafenib (Nexavar®) versus Docetaxel + Placebo in First-Line treatment of patients with HER2-negative, metastatic breast cancer. - MADONNA
niversitätsklinikum Heidelberg0 个研究点目标入组 288 人开始时间: 2008年7月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 288
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Histologically or cytologically confirmed stage IV adenocarcinoma of the breast or inoperable local relapse
- •2. Female patients with HER2 negative breast cancer (latest assessment)
- •3. Patients requiring first line mono-chemotherapy with taxanes
- •4. Age > 18 years.
- •5. ECOG Performance Status of = 2
- •6. Life expectancy of at least 12 weeks.
- •7. Subjects with at least one uni-dimensional (for RECIST) measurable lesion. Lesions must be measured by CT-scan or MRI
- •8. No prior chemotherapy for locally recurrent or metastatic disease
- •9. At least 12 months since prior adjuvant or neoadjuvant taxane therapy; endocrine treatment for early breast cancer is allowed and patients may have failed hormonal therapy in the metastatic stage, if they are ER/PgR-positive.
- •10. Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:
- •11. Hemoglobin > 9.0 g/dl
- •12. Absolute neutrophil count (ANC) >1.500/mm3
- •13. Platelet count ? 100.000/µl
- •14. Total bilirubin < 1,0 times the upper limit of normal
- •15. ALT and AST < 2,5 x upper limit of normal (< 5 x upper limit of normal for patients with liver involvement of their cancer)
- •16. Alkaline phosphatase < 4 x ULN
- •17. PT-INR/PTT < 1.5 x upper limit of normal [Patients who are being therapeutically anticoagulated with an agent such as coumarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists.]
- •18. Serum creatinine < 1.5 x upper limit of normal.
- •19. Signed and dated informed consent before the start of specific protocol procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. History of cardiac disease: congestive heart failure >NYHA class 2; active CAD (MI more than 6 months prior to study entry is allowed); cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted) or uncontrolled hypertension.
- •2. History of HIV infection or chronic hepatitis B or C
- •3. Active clinically serious infections (> grade 2 NCI-CTC version 3.0)
- •4. Prior radiological or clinical evidence of CNS metastases including previously treated, resected, or asymptomatic brain lesions or leptomeningeal involvement by head CT scan or MRI
- •5. Patients with seizure disorder requiring medication (such as steroids or anti-epileptics)
- •6. History of organ allograft
- •7. Patients with evidence or history of bleeding diathesis
- •8. Patients undergoing renal dialysis
- •9. Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis & T1] or any cancer curatively treated > 3 years prior to study entry.
- •Excluded therapies and medications, previous and concomitant:
- •10. Anticancer chemotherapy or immunotherapy (including mistletoe) during the study or within 3 weeks of study entry. Hormone therapy parallel to study treatment is not allowed, but no wash-out period is necessary.
- •11. Radiotherapy during study or within 3 weeks of start of study drug. (Palliative radiotherapy of non-target lesions will be allowed).
- •12. Major surgery within 4 weeks of start of study
- •13. Autologous bone marrow transplant or stem cell rescue within 4 months of study
- •14. Use of biologic response modifiers, such as G-CSF, within 3 week of study entry. [G-CSF and other hematopoietic growth factors may be used in the management of acute toxicity such as febrile neutropenia when clinically indicated or at the discretion of the investigator; however they may not be substituted for a required dose reduction.] [Patients taking chronic erythropoietin are permitted provided no dose adjustment is undertaken within 2 months prior to the study or during the study]
- •15. Investigational drug therapy outside of this trial during or within 4 weeks of study entry
- •16. Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Women enrolled in this trial must use adequate barrier birth control measures during the course of the trial.
- •17. Substance abuse, medical, psychological or social conditions that may interfere with the patient’s participation in the study or evaluation of the study results
- •18. Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study
- •19. Patients unable to swallow oral medications.
研究者
相似试验
进行中（未招募）
不适用
A phase I and randomised phase II study of Docetaxel and RAD001 (Everolimus) in advanced/recurrent or metastatic squamous cell carcinoma of the head and neck - DORAocally advanced or metastatic squamous cell carcinoma of the head and neckMedDRA version: 9.1Level: LLTClassification code 10063569Term: Metastatic squamous cell carcinomaMedDRA version: 9.1Level: LLTClassification code 10060121Term: Squamous cell carcinoma of head and neckEUCTR2007-001951-20-GBniversity College London
进行中（未招募）
1 期
A double blind randomised phase 2 trial of docetaxel with or without AZD6244 in wt BRAF advanced melanoma - Docetaxel +/- AZD6244 in MelanomaAdvanced metastatic melanomaEUCTR2009-018153-23-GBniversity of Oxford80
已完成
不适用
A phase I and randomised phase II study of docetaxel and RAD001 (Everolimus) in advanced / recurrent or metastatic squamous cell carcinoma of the head and neckAdvanced / recurrent or metastsatic squamous cell carcinoma of the head and neck.squamous cell carcinoma of the head and neckCancerISRCTN73814534niversity College London (UCL) (UK)120
未知
2 期
A Randomized, Double-Blind, Phase 2 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapyon-small Cell Lung CancerJPRN-jRCT2080221986Eli Lilly Japan K.K.
尚未招募
2 期
Phase II Trial of Doxycycline with Radiotherapy for Rectal CancerRectal CancerCancer - Bowel - Back passage (rectum) or large bowel (colon)ACTRN12620000815965Dr Natalie Briggs40